Bicara Therapeutics (BCAX) Share-based Compensation (2024 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Share-based Compensation of $5.9 million for Q1 2026, up 69.75% year-over-year from $3.5 million in Q1 2025, and up 167.5% quarter-over-quarter from -$8.7 million in Q4 2025.
Bicara Therapeutics (BCAX) Share-based Compensation (2024 - 2026) Analysis & Trends
Bicara Therapeutics' Share-based Compensation history runs 3 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 69.75% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $4.3 million (down 55.83% YoY), while the FY2025 annual figure was $1.9 million, down 74.61% from the prior year.
- Share-based Compensation for Q1 2026 stood at $5.9 million, up from -$8.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $7.4 million in Q4 2024, with the low at -$8.7 million in Q4 2025.
- The 3-year median for Share-based Compensation is $3.5 million (2025), against an average of $1.9 million.
- Peak annual rise in Share-based Compensation reached 404.45% in 2025, while the deepest fall reached 217.33% in 2025.
- Bicara Therapeutics' Share-based Compensation stood at $7.4 million in 2024, then plunged by 217.33% to -$8.7 million in 2025, then soared by 167.5% to $5.9 million in 2026.
- Business Quant data shows BCAX's Share-based Compensation at $5.9 million in Q1 2026, -$8.7 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 8.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.24 Mn |
| Jun 30, 2026 | 8.24 Mn |
| Mar 31, 2026 | 5.86 Mn |
| Mar 31, 2026 | 5.86 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Jun 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.15 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.15 Mn |